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The Rift Valley fever virus (RVFV) is responsible for a serious mosquito-borne viral disease
in humans and ruminants. The development of a new and safer vaccine is urgently
needed due to the risk of introduction of this arbovirus into RVFV-free continents. We
recently showed that a DNA vaccine encoding eGn, the ectodomain of the RVFV Gn
glycoprotein, conferred a substantial protection in the sheep natural host and that the
anti-eGn IgG levels correlated to protection. Addressing eGn to DEC205 reduced the
protective efficacy while decreasing the antibody and increasing the IFNγ T cell responses
in sheep. In order to get further insight into the involved mechanisms, we evaluated our
eGn-encoding DNA vaccine strategy in the reference mouse species. A DNA vaccine
encoding eGn induced full clinical protection in mice and the passive transfer of immune
serum was protective. This further supports that antibodies, although non-neutralizing
in vitro, are instrumental in the protection against RVFV. Addressing eGn to DEC205
was also detrimental to protection in mice, and in this species, both the antibody and
the IFNγ T cell responses were strongly decreased. Conversely when using a plasmid
encoding a different antigen, i.e., mCherry, DEC205 targeting promoted the antibody
response. Altogether our results show that the outcome of targeting antigens to DEC205
depends on the species and on the fused antigen and is not favorable in the case
of eGn. In addition, we bring evidences that eGn in itself is a pertinent antigen to be
included in a DNA vaccine and that next developments should aim at promoting the
anti-eGn antibody response.
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INTRODUCTION
Rift Valley Fever (RVF) is a mosquito-borne zoonotic viral
disease that primarily affects ruminants. The etiologic agent
Rift Valley Fever virus (RVFV) belongs to the Phenuiviridae
family and is responsible for a high abortion rate in gravid
females, a high mortality rate in newborns, and fetal deformities
in domestic ruminants resulting in economic burden (1).
Human infections with RVFV mainly occur through contact
with body fluids or organs from infected livestock. In human,
self-limiting febrile illness is generally observed and only a
few infected individuals develop severe symptoms including
blindness, encephalitis, hemorrhagic fever, and death. RVFV
has spread outside its endemic areas of mainland Africa to
Madagascar, the Comoros and the Arabian Peninsula, raising
awareness of the risk of introduction and further dissemination
of this pathogen into non-endemic continents where a large array
of competent mosquitoes can transmit the virus. Commercial
attenuated and inactivated veterinary vaccines are available in
endemic countries. However, no safe and efficient vaccine for
veterinary and human use is yet available in non-endemic
countries (2).
Many RVFV candidate vaccines have been developed and
among them, recombinant protein vaccines based on viral
structural proteins showed promising results. Gn ectodomain
(eGn) and Gc proteins confer protective immunity in the sheep
natural host (3). Indeed, Gn and Gc are involved in virus
attachment and fusion with the host cell respectively, and contain
the virus neutralizing epitopes (4). Furthermore, an eGn subunit
vaccine alone confers protection in sheep (5) and an eGn-based
DNA vaccine confers partial protection in mice (6).
DNA vaccination is a promising strategy against emerging
infectious diseases since it is safe, it can be manufactured in
large scale and DNA vaccines are stable (7). Targeting antigen
to selected surface receptors expressed on antigen presenting
cells is an attractive strategy to improve DNA vaccine efficacy
(8). Several studies reported the efficacy of antigen targeting to
DEC205, a receptor expressed on DCs in many species including
on sheep DCs (9, 10). Indeed, DNA vaccine strategies based on
antigen targeting to DEC205 induced strong CD4+ and CD8+
T cell responses and enhanced the antibody (Ab) responses in
mice (11–14), and even in cattle (15). Based on this context,
we recently compared in lambs the efficacy of a DNA vaccine
encoding eGn (peGn) and eGn fused to a single chain fragment
variable (scFv) directed to the ovine DEC205 receptor (pscDEC-
eGn) (16). These DNA vaccine-candidates were co-delivered by
intradermal injection with a plasmid encoding GM-CSF as a
genetic adjuvant (17), followed by surface electroporation (SEP)
to enhance in vivo transfection (18). We have shown that peGn
conferred a good clinical and viral protection in lambs and that
pscDEC-eGn was less protective, it increased the IFNγ T cell
responses and decreased the anti-eGn IgG responses.
The failure of DEC205 targeting to improve the anti-eGn IgG
response in lambs is at odds with other reports showing the
benefits of this targeting (11–14), yet in other species and with
other antigens. This discrepancy may be due to the different
expression profile or intracellular trafficking of DEC205 across
species or, possibly, to the antigenic properties of eGn. In the
present study, we evaluated the efficacy of peGn and pscDEC-
eGn in the mouse reference model, and we sought to get
further insight into the mechanisms underlying the protective
immunity. Altogether our results show that the humoral response
is protective and that DEC205 targeting of eGn is not favorable to
this response in mice, like in sheep. However, we bring evidences
that the DEC205 targeting outcome depends on the species, as
the DEC205 targeting of eGn promoted the IFNγ T cell response
in sheep and decreased this response in mice. Furthermore, we
show that the DEC205 targeting of another antigen (mCherry)
resulted in a mixed outcome, with an increase of the humoral
response and a decrease of the IFNγ response, indicating that
DEC205 targeting outcome also depends on the targeted antigen.
MATERIALS AND METHODS
Cell Lines
Human embryonic kidney cells (HEK293) and African
green monkey kidney cells (VeroE6) were maintained
in culture with Dulbecco’s Modified Eagle medium
(DMEM, Life Technologies), supplemented with 5%
decomplemented fetal bovine serum (FBS), and antibiotic
solution at 37◦C with 5% CO2. CHOmDEC205 (Chinese
hamster ovary expressing murine DEC205) and CHOneo
(negative control) cell lines were maintained in DMEM
supplemented with 5% FBS at 37◦C with 5% CO2 without
antibiotic solution.
RVFV Strains
RVFV strains are classified into a single serotype and low genetic
diversity among strains has been reported (19). The virulent
strain RVFV ZH501, originally isolated from an infected patient
(20), and the attenuated RVFV virus MP-12 strain (21) were
provided by Michèle Bouloy (Paris Pasteur Institute). ZH501
strain was used in challenge experiment and the MP-12 strain
was used in plaque reduction assay. The viruses were amplified
on VeroE6 cells starting at a 0.01 MOI. The supernatant was
harvested after 2 days, centrifuged for 10min at 2,000 rpm and
stored at−80◦C until use.
Production of Anti-RVFV Hyperimmune
Mouse Ascitic Fluid
Anti-RVFV hyperimmune mouse ascitic fluid (HMAF) was
obtained as previously described (16). Balb/c mice were
inoculated intraperitoneally with inactivated RVFV-infected
mouse brain suspensions in Freund’s complete adjuvant on day
0 and 1 and in Freund’s incomplete adjuvant on day 7 and 14. On
day 21 and 28, mice were inoculated with virulent suspension in
Freund’s incomplete adjuvant. Finally, the mice were inoculated
intraperitoneally with TG180 sarcoma cells on day 25. One week
later, ascitic fluid was harvested and stored at−80◦C until use.
Construction and Production of Plasmids
A plasmid encoding Gn glycoprotein ectodomain of RVFV
(peGn) was obtained as previously described (16). In order
to generate targeted antigens to mouse DEC205, we used the
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published sequences of the variable region of the rat heavy (VH)
and light (VL) chains of the anti-mouse DEC205 NLDC-145
clone, separated by a (G4S)4 flexible linker (22) and at its amino-
terminus, we added a signal peptide derived from a murine
IgG (22). A sequence encoding mCherry-6xHis-tag (pscDEC-
mCherry) or eGn (pscDEC-eGn) was fused in frame to the
carboxy terminus of the scFv anti-mouse DEC205 sequence
with a second (G4S)3 linker and the final fusion proteins were
cloned into a pCEP4 mammalian expression vector (Invitrogen).
Plasmids encoding an irrelevant scFv fused to mCherry (pscCtrl-
mCherry) or eGn (pscCtrl-eGn) were also similarly generated
and cloned in the pCEP4 expression vector. The construction
of these vectors encoding the scFv fusions was outsourced
to Synogene, USA. The plasmid encoding murine GM-CSF
(pGM-CSF) was purchased from InvivoGen (USA). A firefly
luciferase expression plasmid (pLuc) was kindly provided by
Stéphane Biacchesi (INRA, France). Plasmid productions for
immunization were prepared using Endofree R© Plasmid Giga Kits
(Macherey-Nagel) and were stored at−20◦C until use.
Plasmids Expression Analysis in
HEK293 Cells
Transfections with pscCtrl-mCherry and pscDEC-mCherry were
performed in HEK293 cells and the supernatants containing
scFv-mCherry proteins were purified by immobilized metal
ion affinity chromatography, using IMAC Sepharose column
charged with Ni2+, equilibrated with low-imidazole buffer
(5mM imidazole, 20mM Tris-HCl (pH 7.4), 150mM NaCl).
After washing, the His-tagged proteins were eluted with high-
imidazole buffer [800mM Imidazole, 20mM Tris-HCl (pH 7.4),
150mM NaCl]. HEK293 cells were transiently transfected with
pcDNA4 (negative control), peGn, pscCtrl-eGn, or pscDEC-eGn
and the supernatants and cells were harvested at 72 h post-
transfection. Cell pellets were lysed in lysis buffer (1% Triton
X-100, 50mM borate, 150mM NaCl, pH 9) at a 1:9 (pellet:buffer
volume) and sonicated. The supernatants of the HEK293 cells
transfected with eGn encoding-plasmids were concentrated 20–
40 times with Amicon R© Ultra centrifugal filter 30K (Millipore).
Samples were resolved on a 12% SDS-PAGE under reducing
conditions and blotted onto nitrocellulose. Blots were incubated
overnight at 4◦C with a polyclonal rabbit anti-dsRed [1:1,000
dilution, Clontech (catalog number 632496, USA)] followed
by the horseradish peroxidase (HRP)-goat anti-rabbit (GAR)
IgG (1:4,000 dilution, KPL, USA) or with anti-RVFV HMAF
(1:1,000 dilution) followed by HRP-rabbit anti-mouse (RbAM)
IgG (1:5,000 dilution, Sigma) in blocking buffer [PBS + 10 %
fat-free milk (w/v)]. Immunoreactive bands were visualized with
ECL substrate (Thermofisher). Image acquisitions were done
with Chemidoc imaging system (Bio-rad).
Staining and Flow Cytometry Analysis
CHOmDEC205 or CHOneo cells were saturated on ice with
RPMI supplemented with 4% horse serum for 30min. To
analyze the expression of DEC205, cells were incubated with
an Alexa 647-conjugated (A647)-rat anti-mouse (RAM) DEC205
IgG2a (NLDC-145 clone, Ozyme), or control A647-RAM IgG2a
(RTK4530 clone, Ozyme) during 30min on ice. To analyze
the binding of scCtrl-mCherry and scDEC-mCherry, the scFv-
mCherry proteins were incubated with CHO cell lines on ice for
45min. To analyze the binding of scDEC-eGn and scCtrl-eGn
on CHOmDEC205 or CHOneo, the concentrated supernatants of
HEK293 transfected cells with pcDNA4, peGn, pscCtrl-eGn, and
pscDEC-eGn were incubated with CHOmDEC205 or CHOneo cells
for 2 h at 4◦C. Cells were then incubated with anti-RVFV HMAF
(1:1,000) and finally with A488-donkey anti-mouse (DAM) IgG
(Jackson ImmunoResearch) (1:200). Dead cells were excluded by
DAPI staining. Flow cytometry acquisitions were done with a
LSR Fortessa flow cytometer (Becton Dickinson) and results were
analyzed using FlowJo 10.0.6 software.
Antigenic Sources for ELISA
Lysates from HEK293 cells transfected with peGn or with
pcDNA4 were used as coating of ELISA wells to detect anti-
eGn Abs and were prepared as described above. Purified mcherry
protein produced in bacteria was used as coating to detect anti-
mCherry Abs by ELISA. To produce mCherry, E.coli BL-21 were
transformed with a plasmid expressing GST-TEV protease site
fused tomCherry (pGEXTEV-4T3-mCherry). Protein expression
was induced by adding 80µg/ml of IPTG into LB medium with
100µg/ml ampicillin at 28◦C overnight. After solubilization of
the pellet with a lysis buffer [Tris 50mM (pH 7.8), NaCl 350mM,
DTT 2mM, benzamidine 4mM, Triton X-100 0.2%+ lysozymes
(10 mg/ml)], the recombinant protein was purified by binding
to glutathione-sepharose 4B beads (GE Healthcare, Uppsala,
Sweden). The tag was then removed by cleavage with TEV
protease, and the mCherry protein released in the supernatant
was collected and stored at−80◦C until use.
Optimization of Plasmid Transfection
Efficacy in Mouse Skin
The experiment was approved by the COMETHEA ethic
committee under the number 2015042719381737. Six to eight-
week-old female Balb/c mice (Janvier, Le Genest, St Isle, France)
were housed under BSL-1 in the animal facility (IERP, INRA,
Jouy-en-Josas, France). In order to evaluate the V/cm parameter
leading to optimal transfection in mouse skin, a pLuc reporter
vector (50 µg) was intradermally injected in the left and right
flanks. The injected skin areas were subjected to SEP using the
CUY 21 EDIT system (BEX, Tokyo, Japan). Disk electrodes
(3mm) were loaded with conductive gel (Alcyon, France) and
6 electric pulses were applied during 10ms with 90ms interval
with escalating pulses from 0 to 2,162 V/cm. Two days later,
skin punch biopsies were harvested and lysed with 150 µl
of lysis reagent (Luciferase Assay System E1500, Promega).
Bioluminescence was measured using the in vivo Imaging System
(IVIS-200, Xenogen, UK) after adding 100µl luciferine substrate.
The optimal V/cm was found to be 1,730 V/cm and was used in
all subsequent experiments (Supplementary Material 1).
Detection of eGn mRNA Expression by
qRT-PCR in the Skin of Vaccinated Mice
The experiment was approved by the ComEth
Anses/ENVA/UPEC ethic committee under the number
08/12/15-8. Ten Balb/c mice were injected intradermally with
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100 µg peGn (3 mice), pscCtrl-eGn (3 mice), and pscDEC-eGn
(4 mice) followed by SEP at 1,730 V/cm, as described above,
4 injection sites per mouse. The 4 injection sites per mouse
(about 60mg skin tissue in total) were homogenized by shaking
with stainless steel bead (Thermo Fisher) in 1ml of TRIzol
reagent (Thermo Fisher Scientific) three times for 30 s using
TissueLyserII (Qiagen). After centrifugation at 1,000 rpm for
5min, total RNA purification were performed according to the
manufacturer’s instructions. The first RNA extract was purified
using a RNeasy MinElute cleanup column. One µg purified RNA
was treated twice with 5 µl of RNAse-free DNAse (30 Kunitz
units, Qiagen) in order to remove any residual DNA plasmid
from the injection (see below for control) and subjected to a
final purification on column. Part of the RNA (100 ng) was
reverse transcribed using the TaqMan R© Reverse Transcription
Reagents (Applied Biosystems). The cDNA (3 ng, duplicates)
was subjected to a PCR reaction with the iTaq Univeral
probes supermix (Biorad) for amplifying a eGn fragment with
forward primer 5′-AGTGCGATGGGCAGTTGTC-3′, reverse
primer 5′-TTCTTGAACACGGCAAATGG-3′ and a 6-FAM-
ACAGCCCATGAGGTC-TAMRA probe (eGn codon-optimized
sequences). The PCR cycling conditions were 95◦C for 30 s,
linked to 40 cycles of 95◦C for 5 s and 60◦C for 30 s. The non-
reverse transcribed RNA (3 ng) of all samples was subjected to
qPCR and no eGn PCR signal could be detected, showing that the
transfected skin purified RNA did not include detectable residual
plasmid. Non-transfected skin was used as negative control
and did not generate any qPCR signal. The relative expression
of eGn mRNA in transfected skin samples was calculated
with the 2−1Ct method using normalization with the GAPDH
gene (forward primer 5′-GGGGTCGTTGATGGCAACA-3′,
reverse primer 5′-AGGTCGGTGTGAACGGATTTG-
3′), confirmed with the HPRT gene (forward primer
5′-CAGGCCAGACTTTGTTGGAT-3′, reverse primer 5′-
TTGCGCTCATCTTAGGCTTT-3′), amplified using the iTaq
UniverSYBR Green (Biorad). The lack of eGn qPCR signal
detection was given a Cq of 40 for the calculation.
Immunizations With
eGn-Expressing Plasmids
The experiment was approved by the ComEth
Anses/ENVA/UPEC ethic committee under the number
08/12/15-8. Six to eight-week-old female Balb/c mice (Janvier,
Le Genest St Isle, France) were housed under BSL-3 conditions
in the animal facility [Plateforme d’Expérimentation Animale
(PFEA)-Anses in Lyon, France]. Mice were vaccinated under
general anesthesia (isoflurane inhalation) two or three times
at 3-weeks intervals, depending on experiments (3 in total),
see figure legends. One hundred µg of peGn, pscCtrl-eGn or
pscDEC-eGn were injected intradermally in the flank together
with 20 µg of plasmid adjuvant (pGM-CSF) or without adjuvant,
followed by SEP at 1,730 V/cm. A non-vaccinated control group
(PBS with pGM-CSF) was included. Sera were collected at
day 0, 21, 42, and 60 post-immunization and splenocytes were
harvested at day 42 or 60 to analyze the T cell responses.
Immunization With
mCherry-Expressing Plasmids
The experiment was approved by the COMETHEA ethic
committee under the number 2015042719381737. Six-week-
old female Balb/c mice were housed under BSL-1 in the
animal facility IERP, INRA, Jouy-en-Josas, France. The same
immunization protocol as described above for immunization
with eGn-expressing plasmids, was performed using pscCtrl-
mCherry and pscDEC-mCherry with and without pGM-CSF.
In these experiments, mice were vaccinated under general
anesthesia (solution of ketamine and xylazine, 50 and 10
mg/kg respectively). Two experiments with pscCtrl-mCherry and
pscDEC-mCherry with and without pGM-CSF were conducted
and gave similar results.
Evaluation of eGn- and mCherry-Specific T
Cell Responses by ELISA
Spleens were collected 3 weeks after the last immunization
and were mechanically dissociated through 100µm nylon mesh
strainers (BD). Splenocyte suspensions were treated with red
blood cell lysis buffer (10mM NaHCO3, 150mM NaCl, 10mM
EDTA). Then 2 × 106 cells were added to wells and re-
stimulated with 5µg/ml overlapping peptides (20 mers, offset
8, Mimotopes, Australia) in X-vivo medium (Ozyme, France)
supplemented with 2% FBS and antibiotic solution at 37◦C
with 5% CO2 for 72 h. Overlapping peptides covering the N-
terminal (AEDPHL [. . . ] LLPDSF) and C-terminal (VCFEHK
[. . . ] NYQCHT) amino-acid sequences of the eGn protein (=
2 peptide pools) or overlapping peptides spanning the entire
mCherry protein sequence (MVSKGE [. . . ] MDELYK) are listed
in Supplementary Material 2. The overlapping peptides were
divided in 2 pools initially diluted in H20:acetonitril (5 mg/ml)
and distributed in 5 µl per well to have 1 µg of each peptide
per well and avoid any toxicity of the H20:acetonitril diluent.
An irrelevant peptide that derives from the HIV polymerase
(IKDFHVYFRESRDALWKGPG) was used to estimate the non-
specific responses (negative control). Cells cultured with ConA
(25µg/ml) were used as positive controls. All supernatants were
assayed for IFNγ, IL-2, and IL-5 by ELISA (RSG ELISA kit,
eBioscience). OD was measured at 450 nm using a TECAN
microplate reader. The specific cytokine concentration was
calculated with a standard curve using recombinant cytokines
and obtained by subtracting OD 450 nm values from wells
stimulated with the irrelevant peptide. In the case of stimulation
with the 2 pools of eGn peptides, the specific cytokines
concentrations obtained with each of the peptide pools were
added to get the final total cytokine concentration.
Evaluation of Anti-eGn and Anti-mCherry
IgG Responses by ELISA
For anti-eGn IgG detection, 96-well-plates Nunc MaxisorpTM
(ThermoFisher) were coated overnight at 4◦C either with 100
µl lysates from HEK293 cells transfected with peGn or with
pcDNA4, diluted 1:500 in PBS+ 0.01% sodium azide. Individual
mouse sera were diluted 1:100 in PBS + 2 % fat-free milk (w/v)
and incubated on the coated plates at 37◦C for 1 h. The plates
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were subsequently incubated with HRP-RbAM IgG (Sigma) at
a 1:4,000 dilution at 37◦C for 1 h. HRP enzymatic activity was
finally revealed using TMB substrate. OD was measured at
450 nm using a TECAN microplate reader. Corrected OD values
were obtained by subtracting the signal of wells coated with
lysates from HEK293 cell transfected with pcDNA4.
For anti-mCherry IgG detection, Half Area Clear Polystyrene
High Bind Microplate 96-well plates (Corning R©) were coated
overnight at 4◦C with 200 ng of recombinant mCherry protein
produced as described above. Coated plates were washed in
PBS 0.05% tween 20 (PBS-T) and saturated in diluent buffer
(PBS-T + 5% FBS) for 1 h at 37◦C. Individual mouse sera were
serially diluted five-fold in PBS-T + 5% FBS starting at 1:100
and incubated on the coated plates at 37◦C for 2 h. Antigen-
bound Abs were revealed with an HRP-GAM IgG (KPL, USA)
at a 1:4,000 dilution in diluent buffer at 37◦C for 1 h. HRP
enzymatic activity was finally revealed using TMB substrate. OD
was measured at 450 nm using a TECANmicroplate reader.
Adoptive and Passive Transfer
The transfer experiment was approved by the ComEth
Anses/ENVA/UPEC ethic committee under the number
11/10/16-7. Six to eight-week-old female Balb/c mice were
immunized 3 times at 3-weeks interval with PBS or peGn
with the pGM-CSF plasmid adjuvant combined with SEP as
described above. Spleen and blood were collected 3 weeks after
the last immunization. Splenocyte suspensions were obtained
as above. Splenocytes from PBS or peGn-immunized mice were
pooled and T cells were isolated by negative selection using a
commercially available murine Pan T cell isolation kit (Miltenyi,
USA) according to the manufacturer’s instruction. The isolated
cells included <1% of non-T cells as assessed by anti-CD3, CD4,
and CD8 staining. Pooled sera of PBS or peGn-immunized mice
were tested by ELISA before transfer (data not shown). Adoptive
and passive transfers were performed with 6-week-old female
Balb/c naïve mice. Three hundred microliters of serum or 107
T cells in 200 µl of saline buffer with 2% horse serum were
intraperitoneally injected per mouse and mice were challenged
the day after.
Challenge
The immunized mice were challenged 3 weeks after the last
immunization with 103 or 104 pfu of the RVFV ZH501 strain
in 100 µl volume by intraperitoneal route. After the challenge,
weight, body temperature and clinical signs were daily monitored
over 21 days. Brain and liver frommoribund mice were extracted
before being euthanized and were immediately stored at −80◦C.
At the end of the study, all animals were euthanized by
cervical dislocation.
RNA Extraction From Liver and Brain and
Detection of Viral Gn RNA by qRT-PCR
Brain and liver were weighed and were homogenized in 500 µl
of DMEM with stainless steel beads (ThermoFisher) 3 times for
30 s at 30Hz using TissueLyserII. After centrifugation at 2,000
rpm for 5min, supernatants were collected. One hundred µl
of homogenate were used for RNA extraction. Total RNA was
extracted with QIAMP viral RNA kit (QIAGEN) according to
the manufacturer’s instructions and eluted in 60 µl RNase-free
water using QIAcube (QIAGEN). For quantification of viral RNA
copies in organs from mice after challenge, a one-step qRT-
PCR was performed using the SuperScript III Platinum One Step
qRT-PCR kit (Invitrogen) as previously described (23). Primers
were designed to amplify a nt 1,164–nt 1,258 Gn sequence of
the M segment: forward primer 5′-AAA GGA ACA ATG GAC
TCT GGT CA-3′, reverse primer 5′-CAC TTC TTA CTA CCA
TGT CCT CCA AT-3′. A fluorescent probe was designed that
hybridizes to the specific PCR product: FAM 5′-AAA GCT TTG
ATA TCT CTC AGT GCC CCA A-3′ TAMRA. A standard
corresponding to a region of the Gn RNA (nt 1,135 to nt 1,286 of
the M segment) was synthetized using the Riboprobe R© in vitro
Transcription Systems (Promega). The qRT-PCR was performed
with 3 µl of sample elution in 20 µl final mix and the cycling
involved the following steps: reverse transcription at 45◦C for
30min, denaturation at 95◦C for 5min, amplification 45 cycles
at 95◦C for 5 s, and 57◦C for 35 s. TaqMan run of experimental
samples contained at least 2 replicates, a known positive control
(RVFV ZH501 strain), a negative control (another Phlebovirus
RNA), and nuclease-free water. The reactions were carried out in
a LightCycler 480 (Roche). The number of viral RNA copies/ml
in each sample was determined using the Gn RNA standard
calibration curve. The results were expressed as the copy number
of viral RNA per g of tissue.
Virus Titration by Plaque Assay
The viral RNA-positive suspensions in qRT-PCR were serially
diluted 1:10–1:106 in DMEM medium and inoculated onto
VeroE6 monolayer cells in 12-well-plates (5 × 105 per
well). One hour after adsorption at 37◦C, 2ml of diluted
carboxymethylcellulose sodium salt with DMEM supplemented
with 5% FBS (v/v) were added to each well and plates were
incubated at 37◦C in 5%CO2 for 5 days. Next, the plaque forming
units (pfu) were revealed by 1% (w/v) crystal violet and the
number of pfu/ml was calculated for each mouse serum.
Plaque Reduction Assay
Neutralizing Ab before challenge were measured as previously
described (16). Sera were diluted 1:10–1:160 in DMEM and
incubated with 100 pfu of MP-12 virus at 37◦C with 5% CO2 for
1 h. Next, the virus and the serum mix were added to VeroE6 cell
monolayers which were further processed as described under the
virus titration by plaque assay. The neutralizing Ab titers were
established as the last dilution which inhibited 50% of the foci
number per well compared to virus-only control titration.
Statistical Analysis
Data were analyzed with the GraphPad Prism 6.0 software.
As data did no pass a normality test (Kolmogorov-Smirnov),
the unpaired non-parametric Mann-Whitney test was used
to compare the T cell responses 2 by 2, the anti-eGn and
anti-mCherry responses between different groups at the
same time point. For anti-mCherry responses, a paired
non-parametric Wilcoxon test was used to compare the
Ab response at different time points vs. at day 0 within
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the same group. A non-parametric Kruskal Wallis test
followed by Dunn’s correction was used to compare the
luciferase signals of transfected skin subjected to SEP vs.
control skin.
RESULTS
A Plasmid Encoding eGn Confers a Total
Clinical Protection Against RVFV Infection
in Mice
We have previously shown that a DNA vaccine encoding eGn
(peGn) administered with a plasmid encoding ovine GM-CSF
was efficient at protecting lambs against RVFV, and that the anti-
eGn IgG levels correlated with protection (16). To investigate
whether this plasmid can also confer protection in mouse, Balb/c
mice were immunized three times using the same delivery
method than the one used in lambs, i.e., intradermal inoculation
followed by surface electroporation [SEP (15), Figure 1A].
Plasmid encoding eGn or PBS combined with a genetic adjuvant
encoding murine GM-CSF (pGM-CSF) were inoculated into the
skin followed by SEP using the optimal electric parameters for
plasmid expression in mouse skin (Supplementary Material 1).
Immunized mice were subsequently challenged with 104 pfu of
the RVFV ZH501 strain and the survival was daily monitored
during 21 days. Immunized mice with peGn + pGM-CSF
were totally protected compared to control group (PBS +
pGM-CSF) (Table 1, Figure 1C). No weight loss was measured
(Table 1) and no apparent clinical signs were observed in
the protected peGn-vaccinated mice. Conversely, 3 out of 5
mice in the control group became moribund, exhibited weight
loss and died after infection. Moreover, viral RNA (ranging
from 2.05 × 109 to 2.28 × 109 viral RNA copies/g) and
infectious viral particles (ranging from 3.67 × 106 to 2.60
× 107 pfu/g) were found in the brain of 2 mice in this
group (Table 1).
Passive Transfer of Serum From
Pegn-Vaccinated Mice Protects Against
RVFV Infection
To evaluate the role of humoral and cellular immunity mediated
by peGn in this protection, we performed transfer experiments.
Naïve recipient mice received 300 µl serum or 1 × 107 purified
T cells from mice immunized with peGn + pGM-CSF, or 300 µl
serum or 1 × 107 purified T cells from mice injected with pGM-
CSF only. One day after passive and adoptive transfers, mice were
challenged with 104 pfu of RVFV (ZH501 strain). The survival
and clinical signs were daily monitored for 21 days (Figure 1B).
The majority of the mice that received the anti-eGn immune
serum were protected (5/7 survival) and did not display clinical
signs. Consistent with these results, no viral particles were found
in the liver (Table 1). Viral RNA was found in brain but at much
lower levels than in the mice injected with the control serum.
Interestingly, all mice that received the control serum died (7/7
death) and exhibited severe clinical manifestations (hypothermia,
significant weight loss, neurological manifestations, and ruﬄed
fur). In this group, viral RNA (ranging from 1.18 × 107 to 6.5 ×
1010 viral RNA copies/g) and viral particles (ranging from 1.11
× 104 to 1.33 × 106 pfu/g) were found in liver, as well as in
the brain (ranging from 1.98 × 1010 to 5.57 × 1012 viral RNA
copies/g and from 3.27 × 108 to 1.25 × 109 pfu/g, Table 1).
This high level of sensitivity in the mice receiving control serum
might be explained by the well described immunosuppressive
effect of IgG systemic injection (24). Recipient mice that received
control T cells or T cells from immune mice were not protected
and most of them succumbed upon infection, like the non-
vaccinatedmice did (Table 1).Mice in these two groups displayed
clinical signs and became moribund and died upon the infection.
Furthermore, viral RNA were found in the liver (ranging from
2.98 × 106 to 1.36 × 107 viral RNA copies/g), both viral
RNA (ranging from 2.13 × 108 to 2.75 × 1013 viral RNA
copies/g), and viral particles (ranging from 5.65 × 107 to 3.84
× 109 pfu/g) were detected in brain of several mice in these
groups (Table 1).
Altogether, this experiment showed that the transfer
of humoral immune effectors from peGn-vaccinated
mice protected mice against RVFV challenge contrary to
the adoptively transferred T cells. This finding supports
the role of anti-eGn immunoglobulins in the protection
against RVFV.
Generation and Expression of Plasmids
Encoding DEC205-Specific scFv Fused to
mCherry or eGn
As said above, we have shown that DEC205 targeting improved
the IFNγ T cell response in lambs but did not enhance the Ab
response and protection against RVFV compared to a plasmid
encoding eGn (16). As this finding contrasts with results from
the literature obtained in other species, mainly in mice, and
with other antigens, we aimed at evaluating the immunogenicity
of DNA plasmids encoding DEC205-targeted eGn in mice as
well as the immunogenicity of DNA plasmids encoding for
another antigen, i.e., mCherry. We generated plasmids encoding
murine DEC205 specific scFv fused to eGn (pscDEC-eGn)
or mCherry (pscDEC-mCherry) as well as plasmids encoding
an irrelevant scFv fused to these antigens (pscCtrl-eGn and
pscCtrl-mCherry) as non-targeted controls (Figure 2A). The
latter controls for the effect of molecular chimerisation of
the antigens fused to a scFv, which was not evaluated in the
sheep model (16). The plasmids were transiently transfected
in HEK293 cells and supernatants were collected for assessing
protein expression in vitro. Western blot analysis revealed a band
corresponding to scCtrl-mCherry (theoretical size: 57.5 kDa for
the chimera, mCherry being 28.8 kDa) and to scDEC-mCherry
(57.6 kDa, theoretical size) (Figure 2B). As also reported in
the case of scDEC-eGn in the sheep study (16), no bands
could be detected by western blot even after concentration of
the supernatants from HEK293 cells transfected with pscDEC-
eGn and pscCtrl-eGn. The lack of detected signal can be
due to the too low capacity of our anti-RVFV HMAF raised
against the whole virus to detect the denaturated eGn chimeric
molecules in Western Blot. Therefore, the expression levels
of these plasmids were analyzed in the lysates of transfected
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FIGURE 1 | Effects of passive and adoptive transfers of immune effectors from peGn-vaccinated mice on the protection against RVFV. Six to eight-week-old female
Balb/c were administered 3 times a day 0, 21, and 42 with 100 µg of peGn + 20 µg of pGM-CSF (immunized groups) or PBS + 20 µg of pGM-CSF (control groups)
by intradermal injection in the flank and immediately followed by surface electroporation (1,730 V/cm). In (A) 3weeks after the last immunization (day 60), immunized
and control mice (n = 5 per group) were challenged with 104 pfu of RVFV (ZH501 strain). In (B) mice were euthanized to collect serum and splenocytes. Naïve
recipient mice received 300 µl of serum or 107 T cells from donor immunized or control mice. Twenty-four hours after the passive (serum) and adoptive (T cells)
transfers, mice were challenged with 104 pfu of RVFV ZH501, n = 5 for adoptive transfer and n = 7 for passive transfer. In (C), the survival was monitored daily for 21
days in the vaccinated (peGn + pGM-CSF) and control (PBS + pGM-CSF) groups (left panel), in the passive transfer groups (middle panel) and in the adoptive
transfer groups (right panel, TL stands for T lymphocytes) and the percentage of survival is shown in Table 1. The syringe drawing is from Servier Medical Art which
provides open source illustrations.
cells where high quantity of proteins is expected to increase
the efficacy of detection. Indeed as previously found in the
sheep model (16), eGn alone was expressed at the expected size
(48.8 kDa) (Figure 2C). Bands corresponding to scDEC-eGn
(76.3 kDa) and scCtrl-eGn fusions (78.6 kDa) were observed
at their expected predicted size and the eGn protein appeared
to be more expressed than scDEC and scCtrl fused with
eGn (Figure 2C).
Binding of DEC205-Specific scFv Fused to
mCherry or to RVFV eGn on the Murine
DEC205 Receptor
In order to further assess the secretion of functional chimeric
antigens, the supernatants of transfected HEK293 were evaluated
for their binding capacity to CHO cells expressing murine
DEC205 receptor (CHOmDEC205) vs. negative control CHO cells
(CHOneo). The parental anti-DEC205 IgG labeled a fraction
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TABLE 1 | Protection mediated by the T cells or sera from peGn-immunized mice upon RVFV challenge.
Liver Brain
Group n◦ of mice surviving
/total n◦ of mice
DPCa % of initial
weightb
Viral RNA
(RNA copy/g)
Viral titer
(pfu/g)
Viral RNA
(RNA copy/g)
Viral titer
(pfu/g)
Control mice
(PBS + pGM-CSF)
2/5 9I 78.4 ND ND ND ND
12I 66.6 1,13E+06 – 2,28E+09 3,67E+06
12I 86.4 1,37E+06 – 2,05E+09 2,60E+07
22 99.1 – – – −
22 95.4 – – – −
Immunized mice
(peGn + pGM-CSF)
5/5 22 101.7 – – – −
22 98.3 – – – −
22 99.5 – – – −
22 100.4 – – – −
22 102.8 – – – −
Transfer control T cells
(PBS + pGM-CSF)
2/5 5I 96.2 ND ND ND ND
8I 70.1 6,21E+06 4,40E+02 7,72E+10 5,65E+07
11I 64.1 2,98E+06 – 3,03E+10 1,94E+08
22 105 – – 2,13E+08 −
22 102.6 – – 4,71E+09 −
Transfer immunized T cells
(peGn + pGM-CSF)
1/5 4I 90.6 ND ND ND ND
8I 69.2 1,36E+07 – 2,75E+13 3,84E+09
8I 76.7 8,70E+06 – 9,58E+09 5,78E+07
9I 81.5 – – 8,31E+11 7,16E+08
22 95.1 – – 1,32E+09 −
Transfer control serum
(PBS + pGM-CSF)
0/7 4I 91.2 6,50E+10 1,33E+06 1,98E+10 −
6I 88.6 ND ND ND ND
8I 73.4 ND ND ND ND
8I 89.3 ND ND ND ND
8I 71.5 1,20E+07 1,11E+04 5,57E+12 1,25E+09
8I 74.2 1,18E+07 – 4,86E+12 8,24E+08
9I 72.2 1,45E+07 – 4,94E+10 3,27E+08
Transfer immunized serum
(peGn + pGM-CSF)
5/7 8I 78.8 ND ND ND ND
10I 82.3 1,70E+06 – 9,02E+09 4,87E+07
22 107.7 – – – −
22 101.5 – – 2,39E+09 −
22 107.3 – – – −
22 107.5 – – 1,26E+09 −
22 108.8 – – 1,50E+09 −
Mice were immunized, transferred, and challenged as described in Figure 1. aDeath, days post challenge (DPC) either due to disease (I) or euthanized during the challenge protocol;
bValues on the day before death; –, non-detected; ND, not done.
of CHOmDEC205 cells, whereas CHOneo were not labeled,
indicating that the stable CHO transfected cells indeed express
the DEC205 molecule, although in a heterogeneous manner
(Figure 2D). The scDEC-mCherry gave a similar staining pattern
as the parental anti-DEC205 mAb (Figure 2E) showing the
specific binding of scDEC on DEC205. Finally, the concentrated
supernatant from HEK293 transfected cells with pcDNA4
(control), peGn, pscCtrl-eGn, and pscDEC-eGn were incubated
with CHODEC205. Similarly to scDEC-mCherry, scDEC-eGn
stained the CHODEC205 cells, whereas the eGn and scCtrl-eGn
controls did not (Figure 2F).
In conclusion, pscDEC-eGn and pscDEC-mCherry express
functional fusion proteins able to specifically bind the murine
DEC205 receptor.
Targeting eGn to DEC205 Decreased the
Anti-eGn IgG Responses in DNA
Vaccination in Mice
In order to assess whether targeting eGn to DEC205 would
promote the anti-eGn IgG response in mice whereas it did not
in sheep, Balb/c mice were immunized with peGn, pscCtrl-eGn,
pscDEC-eGn or PBS combined with or without pGM-CSF as
described above. After 2 immunizations (D42), significant levels
of anti-eGn IgG in serum was measured in peGn-immunized
mice alone or with pGM-CSF (p < 0.05 vs. PBS), and pGM-
CSF did not improve the Ab response (Figure 3A). At D42,
a significant Ab response was detected in mice immunized
with pscCtrl-eGn and pscDEC-eGn with pGM-CSF (p < 0.05
vs. PBS), and the level of anti-eGn IgG Ab was lower in the
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FIGURE 2 | Design and characterization of the pscCtrl or pscDEC plasmids encoding the eGn and mCherry protein fusions with scFvs. (A) Schematic representation
of pscCtrl and pscDEC fused with eGn or mCherry sequences. The pscCtrl (gray background) and pscDEC (white background) constructions include the signal
peptide from VH of murine IgG (SP), the scFv (VH and VL) sequences, and the codon-optimized eGn or the mCherry sequences. The VH and VL sequences derived
from the rat anti-DEC205 NLDC-145 mAb (scDEC) and from a control rat mAb (scCtrl) are connected together with a (G4S)4 linker and the scFv and antigen
sequences are connected with a (G4S)3 linker. In (B) purified scCtrl-mCherry and scDEC-mCherry proteins collected from supernatants of transfected HEK293 cells
were separated by SDS-PAGE under reducing conditions and mCherry was revealed with an anti-mCherry rabbit IgG followed by a HRP-GAR IgG. The predicted
sizes of the expressed chimeric proteins are 57.6 and 57.5 kDa for the scDEC-mCherry and scCtrl-mCherry, respectively. In (C) HEK293 cells were transfected with
pcDNA4 (control), peGn, pscCtrl-eGn, and pscDEC-eGn. The cell lysates were separated by SDS-PAGE under reducing conditions and eGn was revealed with an
anti-RVFV HMAF followed by a HRP-GAM IgG. The predicted sizes of the recombinant proteins are 48.8 kDa for eGn, 78.8 kDa for the scCtrl-eGn, and 79 kDa for the
scDEC-eGn. In (D) CHO cells expressing the murine DEC205 receptor (CHOmDEC205) or CHOneo (control) were labeled with 10µg/ml of A647-anti-DEC205 (gray)
and compared to an A647-isotype control (dash line). In (E) CHOmDEC205 were labeled with 50µg/ml of scCtrl-mCherry and scDEC-mCherry proteins from purified
supernatants. The staining with scDEC-mCherry is depicted (gray) and compared to scCtrl-mCherry (dash line). In (F) CHOmDEC205 were labeled with the 20–40
times concentrated supernatants from the same number of transfected cells with peGn, pscCtrl-eGn, and pscDEC-eGn and eGn was revealed with the RVFV HMAF
(1:1,000) followed with an A488-DAM IgG. The staining is depicted (gray) compared to a control supernatant (pcDNA4 empty vector, dash line). No signal was
obtained with CHOneo cells (not shown).
pscDEC-eGn that in pscCtrl-eGn immunized group. After 3
immunizations (D60), lower Ab responses were observed in
the serum of mice immunized with pscDEC-eGn than in mice
immunized with pscCtrl-eGn in combination or not with pGM-
CSF (p < 0.01 and p < 0.05, respectively). At both time
points, the levels of anti-eGn IgG appear to be higher in
the peGn-vaccinated group than in the pscCtrl-eGn-vaccinated
group (no statistically significant differences). This could be
due to the effect of the chimerization. The ELISA-positive
sera were tested for their capacity to neutralize RVFV in a
reduction plaque assay and none of the sera were neutralizing
at the difference with positive control sera from infected mice
(data not shown).
Altogether, our results indicate that pscDEC-eGn was less
efficient than pscCtrl-eGn and peGn for inducing anti-eGn IgG
responses, independently of the co-administration of pGM-CSF,
and that the anti-eGn IgG induced by our DNA vaccines were
not able to neutralize RVFV in vitro. Thus, as similarly shown in
lamb, DEC205 targeting of eGn is detrimental for the induction
of anti-eGn Ab response.
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FIGURE 3 | Ab responses induced by eGn and mCherry encoding plasmids. (A) Sera from pscDEC205-eGn, pscCtlr-eGn, and peGn (± pGM-CSF) immunized
Balb/c (7 per group) were collected at day 0, 21, 42, 60, and were assayed for the detection of eGn-specific IgG using lysate from HEK293 cells transfected with
peGn as coating. The OD signals at 450 nm from the individual sera collected at each time point and tested at a 1:100 dilution are shown. Each animal is represented
with a distinct symbol and the mean OD value is indicated. P-values were determined using to the Mann-Whitney test (*p < 0.05; **p < 0.01). The significant
difference between the OD values measured at each time point in the vaccinated vs. the PBS group is indicated by a box for clarity (p < 0.05). This experiment has
been repeated twice with similar results. (B) Sera from pscDEC205-mCherry, pscCtlr-mCherry (± pGM-CSF) immunized Balb/c (7 per group) were collected at day 0,
21, 42, 60, and mCherry-specific IgG were evaluated in 1:100 diluted sera using recombinant mCherry as a coating antigen. Each animal is represented with a distinct
symbol and the mean is indicated (n = 6–7 per group). The experiment has been repeated twice with similar results. P-values were determined using to the
Mann–Whitney test (*p < 0.05; **p < 0.01). The significant differences between the OD values measured at day 0 in comparison to days 21, 42, and 60 are indicated
by a box for clarity and were calculated using a non-parametric paired Wilcoxon test (p < 0.01).
DEC205 Targeting of mCherry Promoted
the Ab Responses in DNA Vaccination
in Mice
In order to assess whether the effect of DEC205 targeting on the
Ab response induction could be antigen-dependent, Balb/c mice
were immunized with pscCtrl-mCherry or pscDEC-mCherry
combined or not with pGM-CSF along with SEP. Significant
mCherry-specific Abs were detected in immunized mice at all
time point (p < 0.05 day 0 vs. day 21, 42, 60; Figure 3B).
In absence of pGM-CSF, pscDEC-mCherry promoted a higher
Ab response than pscCtrl-mCherry at day 21 and 42 (p =
0.05 and < 0.05, respectively). The plasmid adjuvant pGM-CSF
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promoted the Ab response induced by pscCtrl-mCherry, which
was not further enhanced by DEC205 targeting. Thus, targeting
eGn and mCherry to DEC205 have contrasted outcomes on the
Ab responses, indicating that the effect of DEC205 targeting
is antigen-dependent.
DEC205 Targeting of eGn and mCherry
Reduced the IFNγ and Not the IL-2T Cell
Responses in Mice
To analyze the eGn-specific T cell responses, total splenocytes
were restimulated in vitro with 2 pools of overlapping peptides
covering the sequence of eGn (N-ter and C-ter peptides) or with
an irrelevant peptide as control. We attempted to investigate the
production of IFN-γ by CD4+ and CD8+ T cells by intracellular
cytokine staining but this method revealed to be not sensitive
enough in our system. We then chose to measure the cytokine
secretion in culture supernatants by ELISA (Figure 4A). Co-
injection of pGM-CSF with peGn or pscCtrl-eGn was able to
trigger significant IFNγ secretion (p < 0.05 vs. PBS) whereas
pscDEC-eGn with pGM-CSF did not. All DNA vaccines were
able to induce significant secretion of IL-2 in absence or in
presence of pGM-CSF (p < 0.05 vs. PBS), and the response
was higher when pGM-CSF was used (p < 0.001, DNA vaccines
vs. DNA vaccines + pGM-CSF). Remarkably, the IL-2 secretion
was even higher in mice immunized with pscDEC-eGn than
pscCtrl-eGn without pGM-CSF (Figure 4A), indicating that
eGn-targeted to DEC205 did not induce T cell anergy. Finally,
no significant IL-5 secretion was measured in the supernatant
of restimulated splenocytes from control and in all immunized
groups (Figure 4A). In order to check that the reduced anti-eGn
antibody and IFNγ T cell response obtained with pscDECeGn
was not due to a defect of plasmid expression in mouse skin, we
transfected peGn, pscCtrl-eGn, and pscDEC-eGn in mouse skin
(3 or 4 mice per plasmid) and detected eGn using qRT-PCR, as
done previously in the sheep study (16). The level of plasmid
expression, which was detected in a fraction of the mice per
group, was similar across plasmids (Supplementary Material 3).
Therefore, we could not detect a defect in the in vivo expression
of pscDECeGn as compared to the other plasmids, which could
explain its altered immunogenicity.
We also analyzed the effect of DEC205 targeting of mCherry
on the T cell responses in mice. The IFNγ T cell responses
was lower in splenocytes from mice immunized with pscDEC-
mCherry compared to pscCtrl-mCherry especially when pGM-
CSF was used, and the IL-2 responses was similar in both
groups, as in the case of eGn expressing vectors (Figure 4B).
However, the IL-5 secretion was higher in the pscDEC-mCherry
immunized group compared to the pscCtrl-mCherry immunized
group, in line with the increased Ab response (p < 0.05
vs. pscCtrl-mCherry).
Altogether, our results indicate that while pscDEC-eGn and
-mCherry were efficient at inducing IL-2 responses, they both
reduced the IFNγ T cell responses compared to vectors encoding
for the untargeted antigens. As higher IFNγ responses were
obtained in sheep by targeting eGn to DEC205 (16), we can
also conclude that the effect of DEC205 targeting on the IFNγ T
cell response depends on the species. Thus, our immunogenicity
results with the eGn and mCherry antigens indicate that the
effects of DEC205 targeting in DNA vaccination depend on the
fused antigen and on the species. This strategy was particularly
inefficient in the case of eGn where protective immunity is
mediated by the humoral IgG response.
Targeting eGn to DEC205 Did Not Enhance
Protection in Comparison to
Non-targeted eGn
We finally assessed the protection induced by scDEC-eGn,
scCtrl-eGn and peGn vectors administered twice together with
pGM-CSF. DNA-vaccinated mice were challenged with 1 × 103
pfu of RVFV ZH501 strain. The survival was daily monitored
during 17 days and the results are depicted in Figure 5. Five-
days post-challenge, mice from control group start to succumbed
upon the virulent ZH501 infection (6/7 death). All peGn
vaccinated-mice survived contrary to non-vaccinated-mice as
previously shown in Figure 1B. In line with the reduced immune
responses, the pscDEC-eGn vaccinated mice were the first to
die among all vaccinated mice (3/7 survival). The pscCtrl-
eGn vaccinated mice were less well protected than the peGn
vaccinated ones, possibly due to chimerization.
To conclude, our results indicate that in agreement with the
reduction of immunogenicity and especially of the anti-eGn
IgG levels, targeting eGn to DEC205 in mice has a negative
effect on protection against RVFV. Altogether, peGn confers the
best protection against RVFV, similarly to what was found in
lambs (16).
DISCUSSION
In the present study, we showed that a DNA vaccine encoding
eGn alone conferred a full protection against a RVFV in mice.
To our knowledge, this is the first study reporting full clinical
protection induced in mice with a DNA vaccine encoding eGn
as only partial protection had been previously achieved with
a eGn encoding plasmid and delivered by gene gun (6). Our
results indicate that anti-eGn Abs are likely to be instrumental in
protection while we could not show the implication of effector T
cells by adoptive transfer. Interestingly, targeting eGn to DEC205
drastically reduced the capacity of eGn to induce IFNγ T cell and
anti-eGn IgG responses in our mouse model. Our results show
that the efficacy of DEC205 targeting on the different arms of
the immune responses depends on the species, as well as on the
vaccine antigen.
Neutralizing Abs are believed to be critical for the protection
against RVFV (2). We showed by transfer experiments that
humoral immune effectors, probably anti-eGn Abs, protected
mice and favored viral clearance in the liver and the brain which
are the main target organs of RVFV (25). The administration of
purified immunoglobulins would be needed to fully demonstrate
their role. However, it is unlikely that another component of
the transferred serum from peGn + pGM-CSF-vaccinated mice
would be implicated, also considering that the control serum
which rather promoted to sensitivity to RVFV, was obtained from
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FIGURE 4 | T cell responses induced by eGn and mCherry encoding plasmids. (A) The spleen cells were collected from mice (7 per groups) immunized with
scDEC205-eGn, scCtlr-eGn, and eGn (± pGM-CSF), 3 weeks after the last immunization (day 60). Splenocytes (2 × 106 cells per well) were re-stimulated in vitro with
overlapping eGn peptides covering the N-terminal and C-terminal parts (5µg/ml) or with an irrelevant peptide (5µg/ml). IFNγ, IL-2, and IL-5 concentration were
measured from cell culture supernatants at 72 h after the stimulation. The specific cytokine secretion was obtained using the signal from irrelevant peptide wells
subtracted from conditions with specific eGn peptides covering the N-terminal or C-terminal parts. The total T cell responses per mouse was calculated by adding the
cytokine concentrations obtained with the 2 peptide pools. Each symbol represents an individual animal and the mean is indicated (n = 5–7 per group). P-values were
determined according to the Mann–Whitney test (*p < 0.05; ***p < 0.001; ****p < 0.0001). The significant differences between the cytokine levels of the PBS vs. the
immunized groups is indicated by a box for clarity (p < 0.05). This experiment has been done twice with the same results. (B) Splenocytes (2 × 106 cells per well)
from the mice of the experiment described in this figure were collected at D60 and re-stimulated in vitro with overlapping mCherry peptides (5µg/ml) or with an
irrelevant peptide (5µg/ml). IFNγ, IL-2, and IL-5 concentration were measured from cell culture supernatants at 72 h after the stimulation. The specific cytokine
secretion was obtained from irrelevant peptides wells subtracted from condition with specific mCherry peptides. Each symbol represents an individual animal and the
mean is indicated (n = 7 per group). This experiment with pGM-CSF has been done twice with the same results. P-values were determined according to the
Mann–Whitney test (*p < 0.05; ***p < 0.001).
mice injected with pGM-CSF plasmid alone. Surprisingly the
serum from peGn-vaccinated mice did not display any RVFV-
neutralizing properties in vitro. The ability of Ab to exert viral
neutralization is often related to the natural conformation of
the vaccine antigen. In our case, expression of eGn by the
plasmid vaccine in vivomay display differential post-translational
modifications or folding than the subunit eGn protein vaccines
that were able to induce neutralizing Ab in mice and sheep
(5, 26). The eGn Abs induced by our DNA vaccine may also
contribute to the viral clearance by other mechanisms such
as complement-dependent inhibition or Ab-dependent cellular
cytotoxicity (ADCC) or phagocytosis which remains to be
investigated. In addition, it is possible that the classical in vitro
neutralization assay does not faithfully recapitulate the in vivo
neutralization and that the mouse sera were neutralizing in vivo.
Finally, we have also shown that anti-eGn IgG levels correlated
with protection in peGn-vaccinated lambs, and that these sheep
IgG were also not neutralizing in vitro (16).
The targeting of vaccine antigen to DEC205 has been reported
to be particularly efficient at promoting Th1 CD4+ T and CD8+
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FIGURE 5 | Protection induces by peGn, pscCtrl-eGn, and pscDEC-eGn against RVFV infection. Six to eight-week-old female Balb/c were immunized twice at day 0
and 21 with 100 µg of peGn, pscCtrl-eGn, pscDEC-eGn, or saline buffer (PBS) with 20 µg of pGM-CSF as an adjuvant. The plasmids were intradermally injected in
the flank and immediately followed by surface electroporation (1,730 V/cm). Three weeks after the last immunization, mice were challenged with 103 pfu of RVFV
(strain ZH501). The survival was daily monitored for 17 days and the percentage of survival is shown (n = 7 per group).
T cell responses, both in the case of protein vaccines (27, 28)
and DNA vaccines (11–15). However, one of us reported that
a DNA vector encoding influenza haemagglutinin targeted to
DEC205 and delivered in the muscle by electroporation in mice
led to a strong reduction of the IFNγ T cell response (29),
as we also found here, both in the case of DNA encoding for
DEC205-targeted eGn and mCherry antigens. In another study,
we also reported that a DNA vector encoding for the Simian
Immunodeficiency Virus p27 protein targeted to DEC205,
delivered in muscle by electroporation, strongly reduced the
IFNγ T cell response in monkey (30) whereas, as said above, we
found that the IFNγ T cell response was enhanced by targeting
eGn to DEC205 in sheep in DNA vaccination (16). The reasons
for the discrepancies between all these studies are unclear and
might reside in the ambivalent effect of DEC205 targeting which
promotes effector T cell responses when the targeted DC are
activated by adjuvants whereas it promotes regulatory T cell
responses when the targeted DC are at steady state (27, 31).
Electroporation induces an inflammatory response which was
proposed to have adjuvant properties (32). However, in the case
where plasmid expression is prolonged beyond the inflammatory
response, the regulatory T cell response (Treg) may be the
dominating response. Indeed influenza haemagglutinin targeted
to DEC205 induced a potent Treg response in the mouse local
lymph nodes (29). However, in our work, the total Foxp3+
T cell numbers in spleen and the secretion of IL-10 in eGn-
restimulated splenocytes were not enhanced by the DEC205
targeting of eGn (data not shown), but we may have missed the
Treg response if mainly located in the lymph nodes and/or if
the response was antigen-specific. In any event, we also found
that the reduction of the IFNγ responses induced by DEC205-
targeted eGn andmCherry was particularly clear when pGM-CSF
was co-injected. Whereas, pGM-CSF potently activated the T
cell response induced by the plasmids encoding the non-targeted
antigens, it may have induced the recruitment of immature
dendritic cells (33), whose targeting via DEC205 would have
further promoted a regulatory response.
DEC205 targeting of antigens has also been found efficient at
promoting Ab responses, depending on the presence of adjuvant
in the case of protein vaccines (34) and in the context of DNA
vaccines in several instances (11–15). Interestingly however, we
show here that this promotion can depend on the antigen fused
to the scFv anti-DEC moiety, as an enhancement was found
in the case of mCherry but a reduction in the case of eGn.
We can speculate that these opposite outcomes may depend
on the altered or maintained antigen conformation induced by
the fusion with scFv, on the interactions of the antigens with
other immune receptors together with the targeted receptor, on
the kinetics of internalization of the fusion protein affecting
the duration of the interaction with the B cell receptor, or on
the presence of T cell epitopes favorable to the induction of T
follicular and Th2 helper response (35). In favor of this later
hypothesis, we found that pscDEC-mCherry and not pscDEC-
eGn induced higher IL-5 responses than the plasmid encoding for
the non-targeted antigens, and in addition pGM-CSF promoted
the IL-5 response to mCherry and far less so to eGn.
The difference of outcome with DEC205 targeting of eGn
between 2 different species regarding the IFNγ T cell response
is puzzling. It is possible that the duration of plasmid expression
was different between the two species, leading to target steady
state DC in the case of mice and not in sheep. In addition,
the routing of DEC205 may follow different maturation and
compartment pathways and the effect of the combination with
GM-CSF may induce different signaling.
Altogether we showed that a DNA vaccine encoding eGn
is efficient at fully protecting mice from RVFV pathogenesis
and we bring evidences that the Ab response is instrumental
in this protection. Therefore, the improvement of DNA vaccine
for application in target species should aim at inducing high
anti-eGn Ab levels. We found that targeting eGn to DEC205
was not suitable for that purpose, both in mice and in
sheep. Other DC receptors known to promote Ab response
should be evaluated such as CLEC9A (36, 37). Our work also
illustrates that the outcome of antigen-DC targeting remains
unpredictable and at least depends on the antigen and the
species. Knowledge in the mechanistic clues governing DC
targeting efficacy is urgently needed to improve the success of
this strategy.
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